BRAF V600E MUTATION PRESENT
Clinical trials for BRAF V600E MUTATION PRESENT explained in plain language.
Never miss a new study
Get alerted when new BRAF V600E MUTATION PRESENT trials appear
Sign up with your email to follow new studies for BRAF V600E MUTATION PRESENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Drug combo shows promise against rare brain tumor
Disease control OngoingThis phase II trial tests two targeted drugs, vemurafenib and cobimetinib, in 24 people with a rare type of brain tumor called papillary craniopharyngioma that has a specific genetic mutation (BRAF V600E). The drugs work by blocking enzymes that help tumor cells grow. The main go…
Matched conditions: BRAF V600E MUTATION PRESENT
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo offers hope for hard-to-treat thyroid cancer
Disease control OngoingThis study tests whether two targeted drugs (encorafenib and binimetinib) with or without an immunotherapy drug (nivolumab) can shrink or slow advanced thyroid cancer that has spread and no longer responds to standard radioactive iodine treatment. About 24 adults with a specific …
Matched conditions: BRAF V600E MUTATION PRESENT
Phase: PHASE2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC